Chairman of the Board
Members of the Cyxone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.
Chairman of the Board
Born 1960. Chairman of the Board since 2023.
Michael Oredsson, holds a business degree with an international focus from Lund University. During his career, he has experience from leading positions in multinational food companies such as Nestlé, Coca-Cola Company and Mars Inc. in Sweden, Germany and France and between 1993 and 2000 within Pharmacia in Sweden and Australia. Since 2000, Michael has worked as CEO of a number of listed and privately owned life science companies in Sweden, Denmark, Australia and Belgium, including Probi and BioInvent in Lund. In addition, he has held about ten board assignments, three of which as chairman of the board.
Born 1966. Board Member since 2015.
Dr Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.
Bert Junno owns 400,000 shares in Cyxone. Junno further owns 1,788,732 shares in Cyxone through Fornio AB.
Born 1962. Board Member since 2023.
Jürgen Reess, has an MD and PhD from the University of Ulm. He is a physician specialized in neurology with over 20 years of experience in operational and strategic clinical development of new drugs, most recently as Corporate Senior Vice President of International Project Management at Boehringer Ingelheim, Human Pharma. Jürgen Reess led the development, approval and launch of several blockbuster therapies for autoimmune and CNS diseases at Boehringer Ingelheim. Jürgen Reess is co-founder of the US-based biotech company MoglingBio and currently Chief Medical Officer of SciRhom and member of the CNS Scientific Advisory Board of Pivotal bioVenture Partners.
Born 1967. Board Member since 2023.
Andrew Scorey, attained Bachelor of Business studies from the University of Cape Town, along with Executive degrees in Business and Marketing. Andrew has a broad experience from senior roles in general management and marketing from the pharmaceutical and food industries. He has also held several international roles within Abbot Corporation, Nestlé and Novartis, operating in the United States, South America, South Africa, the United Kingdom, Switzerland, Southeast Asia and China.